Psychiatry

In an interview, Hassan Dashti, PhD, RD, discusses the main takeaway of a study on anorexia nervosa being associated with the morning chronotype.

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

A new study found individuals with anorexia nervosa were associated with having a morning chronotype and vice versa.

Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.

Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.

A nationwide Taiwan-based study found benzodiazepine use during pregnancy was linked to roughly a 70% increased risk of miscarriage.

After participants with autism wore biosensors tracking physiological signals, a logistic regression predicted aggressive behaviors 3 minutes before it happened.

In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.

Miller discusses the EMERGENT-2 trial and the benefits of xanomeline-trospium for treating adults with schizophrenia, for which the treatment is currently awaiting FDA decision.

Jennifer Mitchell, PhD, discusses MAPS Public Benefit Corporations’ recent New Drug Application submission for MDMA-Assisted Therapy for PTSD and what the treatment’s potential approval could mean for people with PTSD.

The FDA approved zuranolone for postpartum depression in August, and the drug recently hit the market for patients this month. Experts are celebrating its delivery of care and rapid response rate.

Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.

A phase 2b clinical trial met its primary endpoint with positive topline results, showing MM-120 (lysergide d-tartrate) can reduce symptoms of generalized anxiety disorder, reflected in the Hamilton Anxiety rating scale scores.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.

Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.

In an interview with HCPLive, Rishi Kakar, MD, discussed how KarXT is a novel molecule unique from currently available schizophrenia treatments.

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.

From 2018 to 2021, the deaths among U.S. pregnant and postpartum women aged 35 – 44 years old more than tripled, a new study found.

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.

Children of mothers in minority group were associated with a higher likelihood of ASD diagnosis, but only children of White mothers had ASD associated with neighborhood disadvantages.

A new study found that 25% of PSG-PTSD were related to metabolic traits.

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.

Papola comments on the study he led which found that cognitive behavior therapy is the most effective form of treatment for GAD.

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.